Magnesium for sleep and stress: what to expect

What magnesium studies found for sleep and stress, which forms were studied, and what to consider for safety.

Key points

  • In healthy adults with poor sleep, a magnesium bisglycinate and glycine complex produced a small additional reduction in insomnia severity over four weeks compared with placebo. The result remained uncertain, so any possible improvement in sleep may be small. [1] See the evidence 1
  • The same study found no convincing difference in sleep quality or daytime sleepiness. No additional improvement over placebo was detected for these measures. [1] See the evidence 1 2
  • Studies of healthy adults with poor sleep and people with fibromyalgia found no convincing overall reduction in stress measures; in the first group no difference in anxiety scores was found either. No convincing overall effect was detected in these groups over four weeks. [1] [2] See the evidence 1 2 3

Practical guide

Check the conclusions and whether they apply to your situation.

Magnesium has been studied for poor sleep and stress. Results differ by measure and apply to specific groups and formulations.

What to expect

Why these conclusions

Sleep and stress results

In a study of healthy adults aged 18–65 with poor sleep, the complex provided 250 mg elemental magnesium and 1,523 mg glycine daily for 28 days. Insomnia severity fell by an additional 1.6 points versus placebo, but the rounded interval includes no difference; glycine’s contribution was not studied separately. [1]

No convincing additional difference in sleep quality or daytime sleepiness was found in the same study. [1]

In healthy adults with poor sleep, the same complex showed no convincing difference in stress or anxiety scores. In people with fibromyalgia and stress, magnesium chloride providing 100 mg elemental magnesium daily for 28 days also showed no convincing overall advantage on the stress measure. [1] [2]

ISI fell by an additional 1.6 points; the rounded confidence interval includes no difference. Glycine’s effect was not studied separately.

ParameterData
ResultISI fell by an additional 1.6 points; the rounded confidence interval includes no difference. Glycine’s effect was not studied separately.
Participants155 randomised healthy adults aged 18–65 with poor sleep; 153 were included in the primary analysis
FormMagnesium bisglycinate and glycine complex
Dose250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
Dose basis250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
Comparatorplacebo or control under comparable conditions
Duration28 days
Confidence2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The conclusion is limited to the specified group, dose and outcome. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis.
Evidence base1 publication described
Sources[1]

No convincing additional difference in SQS was found; a small effect cannot be ruled out.

ParameterData
ResultNo convincing additional difference in SQS was found; a small effect cannot be ruled out.
ParticipantsHealthy adults aged 18–65 with poor sleep
FormMagnesium bisglycinate and glycine complex
Dose250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
Dose basis250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
ComparatorPlacebo
Duration28 days
Confidence2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The conclusion is limited to the specified group, dose and outcome. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis.
Evidence base1 publication described
Sources[1]

No convincing difference in daytime sleepiness was found.

ParameterData
ResultNo convincing difference in daytime sleepiness was found.
ParticipantsHealthy adults aged 18–65 with poor sleep
FormMagnesium bisglycinate and glycine complex
Dose250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
Dose basis250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
ComparatorPlacebo
Duration28 days
Confidence2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The conclusion is limited to the specified group, dose and outcome. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis.
Evidence base1 publication described
Sources[1]

The PSS comparison showed no convincing difference; participants were not selected for stress.

ParameterData
ResultThe PSS comparison showed no convincing difference; participants were not selected for stress.
ParticipantsHealthy adults with poor sleep
FormMagnesium bisglycinate and glycine complex
Dose250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
Dose basis250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
Comparatorplacebo or control under comparable conditions
Duration28 days
Confidence2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The question specifically concerns people with poor sleep and PSS stress or PHQ anxiety scores. It does not imply a general conclusion about treating anxiety. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis.
Evidence base1 publication described
Sources[1]

No difference was found on the PHQ-4 anxiety subscale; small effects cannot be ruled out.

ParameterData
ResultNo difference was found on the PHQ-4 anxiety subscale; small effects cannot be ruled out.
ParticipantsHealthy adults with poor sleep
FormMagnesium bisglycinate and glycine complex
Dose250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
Dose basis250 mg elemental magnesium and 1,523 mg glycine daily, two capsules
Comparatorplacebo or control under comparable conditions
Duration28 days
Confidence2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The question specifically concerns people with poor sleep and PSS stress or PHQ anxiety scores. It does not imply a general conclusion about treating anxiety. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis.
Evidence base1 publication described
Sources[1]

Mean score on day 28 was 21.8 versus 21.6; no convincing overall advantage was found.

ParameterData
ResultMean score on day 28 was 21.8 versus 21.6; no convincing overall advantage was found.
ParticipantsPatients with fibromyalgia and stress
Formmagnesium chloride
Dose100 mg elemental Mg/day
Dose basis100 mg elemental Mg/day
Comparatorplacebo or control under comparable conditions
Duration28 days
Confidence2/4: Risk of bias: Attrition, incomplete original plans or limited assessment of individual trials’ risk.; Consistency: No serious unexplained heterogeneity was found for the specific outcome. There is no additional reduction in confidence on this basis.; Applicability to the specified group: The conclusion is limited to the specified group, dose and outcome. There is no additional reduction in confidence on this basis.; Precision: A small sample and a wide or unreported interval leave substantial uncertainty.; Possible publication bias: No specific reason for a separate reduction; unpublished data cannot be ruled out. There is no additional reduction in confidence on this basis.
Evidence base1 publication described
Sources[2]

High doses of magnesium from supplements or medicines often cause diarrhoea, sometimes with nausea and abdominal cramps; toxicity risk is higher with impaired kidney function.

ParameterData
ResultHigh doses of magnesium from supplements or medicines often cause diarrhoea, sometimes with nausea and abdominal cramps; toxicity risk is higher with impaired kidney function.
ParticipantsGeneral information; especially with reduced kidney function
FormNot applicable: the statement concerns magnesium or the category as a whole; the source does not specify a particular form.
DoseThe source does not specify a universally safe dose for an individual
Dose basisThe source does not specify a universally safe dose for an individual
ComparatorNot applicable: descriptive fact, without a comparative study.
DurationNot applicable: descriptive fact; intervention duration is not assessed.
ConfidenceA numerical effectiveness rating does not apply to this reference entry.
Evidence baseNamed publications: 1
Sources[3]

NIH states a tolerable upper level of 350 mg magnesium daily from supplements and medicines for adults; this is a limit for the healthy population, not a target dose.

ParameterData
ResultNIH states a tolerable upper level of 350 mg magnesium daily from supplements and medicines for adults; this is a limit for the healthy population, not a target dose.
ParticipantsHealthy adults
FormNot applicable: the statement concerns magnesium or the category as a whole; the source does not specify a particular form.
Dose350 mg/day elemental magnesium from supplements and medicines
Dose basis350 mg/day elemental magnesium from supplements and medicines
ComparatorNot applicable: descriptive fact, without a comparative study.
DurationNot applicable: descriptive fact; intervention duration is not assessed.
ConfidenceA numerical effectiveness rating does not apply to this reference entry.
Evidence baseNamed publications: 1
Sources[3]

More details

Amount and safety

High doses of magnesium from supplements or medicines can cause diarrhoea, nausea and abdominal cramps; toxicity risk is higher with reduced kidney function. If the expected change in sleep does not occur, do not automatically increase the dose; discuss continuing problems with a professional. [3]

In the US, the tolerable upper intake level for healthy adults is 350 mg elemental magnesium daily from supplements and medicines. This is a limit, not a recommended target dose. [3]

Sources

  1. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/40918053/
  2. Short-Term Magnesium Therapy Alleviates Moderate Stress in Patients with Fibromyalgia: A Randomized Double-Blind Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/35631229/
  3. Magnesium: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/

Methodology: Subpages evidence-led supplement pipeline v1

Ingredient overview: Magnesium